Breaking News Instant updates and real-time market news.

MU

Micron

$35.48

1.74 (5.16%)

, BMY

Bristol-Myers

$47.16

-0.8 (-1.67%)

08:55
01/10/19
01/10
08:55
01/10/19
08:55

Notable open interest changes for January 10th

Wednesday's total option volume of 21.0 million contracts resulted in net open interest growth of 3.30 million calls and 3.26 million puts. Micron (MU), Bristol Myers Squibb (BMY), Bank of America (BAC) and Apple (AAPL) saw the greatest growth. Top five new positions opened include 26k Bristol Myers Squibb (BMY) Jan-20 40 puts, 25k Southwestern Energy (SWN) Feb-19 4 puts, 24k Bristol Myers Squibb (BMY) Jun-19 55 calls, 19k Bank of America (BAC) 1/11 weekly 26.5 calls and 17k GoPro (GPRO) Feb-19 5 puts.

MU

Micron

$35.48

1.74 (5.16%)

BMY

Bristol-Myers

$47.16

-0.8 (-1.67%)

BAC

Bank of America

$25.76

0.25 (0.98%)

AAPL

Apple

$153.30

2.53 (1.68%)

  • 16

    Jan

  • 24

    Jan

  • 28

    Jan

  • 12

    Feb

  • 28

    Feb

  • 03

    Mar

  • 18

    May

  • 20

    May

  • 28

    May

MU Micron
$35.48

1.74 (5.16%)

01/07/19
01/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Outperform from Market Perform at BMO Capital with analyst Richard Carlson citing a "brighter spotlight" being placed on the GM Cruise model in 2019 leading to more appropriate value being priced into the shares. 2. Alphabet (GOOG, GOOGL), Adobe (ADBE), and Salesforce (CRM) were upgraded to Buy from Hold at Pivotal Research. 3. Citi (C) upgraded to Outperform from Neutral at Macquarie with analyst David Konrad saying despite macro uncertainties, he sees Citi's stock as compelling due to his expectations for improving performance, continued operating leverage and credit risk concerns that he views as overdone. 4. Micron (MU) upgraded to Outperform from Market Perform at BMO Capital with analyst Ambrish Srivastava citing valuation. 5. Dillard's (DDS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he sees a more balanced risk/reward with the stock underperforming the over the past few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/08/19
NEED
01/08/19
NO CHANGE
NEED
Hold
Needham stays Hold on Micron, says Samsung confirmed weakening outlook
Needham analyst Rajvindra Gill keeps a Hold rating on Micron Technology (MU) after Samsung (SSNLF) lowered its preliminary outlook for Q4. Similar to Micron, Samsung cited excess inventory at its hyperscaler customers and weaker than expected demand in smartphones, Gill tells investors in a research note. Samsung also reiterated a similar view of Micron's that it expects a second half of 2019 rebound driven by new central processing unit architectures and launches of new smartphones, adds the analyst. Gill, however, believes visibility into the second half of 2019 remains limited. Based on industry conversations, he thinks excess inventory at hypersacalers will persist for at least another 3-6 months. Further, the slowing Chinese economy makes him cautious on overall demand conditions in the first half of the year. As such, Gill says that while Micron is trading at historical low valuation multiples, the stock has further downside if demand conditions worsen. Shares of Micron are down 3%, or $1.11, to $32.89 in morning trading.
01/09/19
01/09/19
UPGRADE
Target $52

Outperform
Micron upgraded to Outperform at Bernstein on attractive risk/reward
As previously reported, Bernstein analyst Mark Newman upgraded Micron to Outperform from Market Perform saying that although he still sees up to 20% potential further downside in the worst scenario, the risk/reward is now too attractive to ignore. The analyst also lowered his price target on the shares to $52 from $60.
01/09/19
BERN
01/09/19
UPGRADE
BERN
Outperform
Micron upgraded to Outperform from Market Perform at Bernstein
BMY Bristol-Myers
$47.16

-0.8 (-1.67%)

01/04/19
WELS
01/04/19
NO CHANGE
Target $84
WELS
Market Perform
Celgene price target cut to $84 from $90 at Wells Fargo
Wells Fargo analyst Jim Birchenough maintained a Market Perform rating on Celgene (CELG) but cut his price target to $84 following yesterday's proposed acquisition by Bristol-Myers (BMY). In a research note to investors, Birchenough says he continues to see fundamental risk to both Celgene value and deal closing with poor visibility on long-term growth for the combined company and risk to ongoing Revlimid patent litigation. With the debate on Revlimid generic timing and impact likely to remain on overhang, the analyst believes that the proposed acquisition gives greater leverage to generics, reduces the likelihood of a reasonable settlement and complicates any settlement process.
01/04/19
BARD
01/04/19
UPGRADE
Target $92
BARD
Outperform
Baird upgrades Celgene to Outperform, says deal discount looks high
As reported previously, Baird analyst Brian Skorney upgraded Celgene (CELG) to Outperform from Neutral. The analyst believes the current price discount to the Bristol-Myers (BMY) deal price does not makes sense based on the probability of the deal closing in the high $90's. He attributes a 35-40% probability of the deal falling through, but he is more bullish on the deal as management is now shown to be willing sellers. Skorney has a $92 price target on Celgene shares, which are up about 2% in pre-market trading to $82 per share.
01/04/19
EDJN
01/04/19
DOWNGRADE
EDJN
Hold
Bristol-Myers downgraded to Hold from Buy at Edward Jones
01/04/19
01/04/19
DOWNGRADE

Outperform
BeiGene downgraded to Outperform at CLSA as Celgene goes 'from friend to foe'
As previously reported, CLSA analyst David Li downgraded BeiGene to Outperform from Buy following the news yesterday of Bristol-Myers' (BMY) proposed acquisition of Celgene (CELG) in a note titled "From friend to foe." He thinks Celgene is unlikely to continue to cooperate with BeiGene on its PD-1 after the deal goes through and also worries about the three commercialized products licensed from Celgene and about the company selling out of its BeiGene stake, he tells investors. He lowered his price target on BeiGene shares to HK$89.86 from HK$121.34.
BAC Bank of America
$25.76

0.25 (0.98%)

01/09/19
01/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at HSBC. 2. Bank of America (BAC) upgraded to Buy from Hold at Edward Jones and to Buy from Neutral at UBS. 3. Wendy's (WEN) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Bittner saying his work reveals an "intriguing setup" as Street's earnings and free cash flow estimates through 2020 have reset to levels that create an improved scenario for meets or beats, same-store sales appear to have drivers to accelerate into 2019 against conservative sell-side forecasts of sub-2% perpetually, new international strategy could unlock faster-than-expected long-term unit growth, and valuation at about 8% free cash flow yield implies very attractive upside/downside case against a highly stable financial model. 4. Akamai (AKAM) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brandon Nispel saying his data tracker suggests upside to Q4 revenue, decreasing the risk to a Q1 and 2019 guide below expectations. 5. Foot Locker (FL) upgraded to Outperform from Neutral at Baird with analyst Jonathan Komp citing its relative valuation and strong backward looking indicators providing reason for optimism. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/19
EDJN
01/09/19
UPGRADE
EDJN
Buy
Bank of America upgraded to Buy from Hold at Edward Jones
01/09/19
UBSW
01/09/19
UPGRADE
Target $32
UBSW
Buy
Bank of America upgraded to Buy from Neutral at UBS
UBS analyst Saul Martinez upgraded Bank of America (BAC) to Buy while lowering his price target for the shares to $32 from $33. The current share price offers an attractive entry point for a "leading franchise with proven risk and expense discipline and above peer profitability," Martinez tells investors in a research note. He believes that even with slowing revenue growth, Bank of America should continue improving efficiency metrics. Further, the company looks "comparatively well positioned to withstand a turn in credit," adds the analyst. Citigroup (C) remains Martinez's top pick among money centers.
01/08/19
UBSW
01/08/19
UPGRADE
UBSW
Buy
Bank of America upgraded to Buy from Neutral at UBS
AAPL Apple
$153.30

2.53 (1.68%)

01/09/19
MSCO
01/09/19
NO CHANGE
Target $211
MSCO
Overweight
Apple Services deceleration this quarter likely temporary, says Morgan Stanley
After Apple provided the quarterly disclosure of the reclassification of its FY18 Services revenue to account for how the company now accounts for the amortization of the deferred value of Maps, Siri and free iCloud services, Morgan Stanley analyst Katy Huberty said the data clarified that December 2018 Services growth was 18.3% year-over-year. She believes the Services deceleration this quarter is more temporary in nature and largely attributes it to AppleCare, which was impacted by the year-over-year decline iPhone sales. Huberty maintains her Overweight rating and $211 price target on Apple shares.
01/09/19
HSBC
01/09/19
NO CHANGE
Target $160
HSBC
Hold
Apple price target lowered to $160 from $200 at HSBC
HSBC analyst Erwan Rambourg, who had downgraded Apple shares to Hold from Buy on December 4, said that although he had expected challenges for Apple in China, the intensity has "surprised to the downside." Given that the China situation remains complex, and patent disputes adds to the headwinds, he lowered his revenue estimates for 2019-21 by 5%-7% and cut his net income estimates by 8%-9%. Meanwhile, the iPhone's longer replacement cycle may hamper shipments in developed markets, said Rambourg, who lowered his price target for Apple shares to $160 from $200 and maintains a Hold rating.
01/09/19
OPCO
01/09/19
NO CHANGE
OPCO
Perform
Oppenheimer says 'rare miss' at Skyworks likely hints at downside risk for peers
Oppenheimer analyst Rick Schafer lowered his estimates for Skyworks (SWKS) after the company negatively pre-announced December quarter revenues and EPS, stating that he blames the majority of the company's "rare miss" on disappointing Apple (AAPL) iPhone units, though he also believes Samsung (SSNLF) and China OEMs contributed. Management did not offer a March quarter outlook, so estimates could come down again when Skyworks reports in a few weeks, warned Schafer, who thinks the pre-announcement likely hints at downside risk at peers such as Cirrus Logic (CRUS) and Qorvo (QRVO). He keeps a Perform rating on Skyworks shares, which are up 2% to $66.66 in morning trading.
01/10/19
LOOP
01/10/19
NO CHANGE
Target $92
LOOP
Buy
Skyworks price target lowered to $92 from $102 at Loop Capital
Loop Capital analyst Cody Acree lowered his price target on Skyworks (SWKS) to $92 after the company cut its Q1 earnings guidance that also followed a negative pre-announcement from Apple (AAPL). The analyst keeps his Buy rating on the stock however, stating that he was most impressed with the 4% rise in its price in spite of the guidance cut, which he believes suggests that the broad sell-off in the chip industry is a "solid indication" of the sector being oversold. Acree adds that the headwinds from tax-loss selling and portfolio rebalancing should be largely in the past, and expects the constructive U.S.-China trade talks to bring back investors looking for "strong fundamentals".

TODAY'S FREE FLY STORIES

02:50
01/22/19
01/22
02:50
01/22/19
02:50
General news
FX Update: The Dollar and Yen have traded firmer »

FX Update: The Dollar…

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.